Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

In a recent study published in Nature Methods, researchers developed "scAtlasVAE," a deep-learning model to integrate large-scale single-cell ribonucleic acid (RNA) sequencing (scRNA-seq) data, ...

A recent Science study explored how intranuclear metabolic enzymes establish the link between locus-specific epigenetic reprogramming of T cells and nutrient availability. Persistent antigen ...

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...